+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Leukemia Patient Grants

Leukemia Research Foundation

Receiving treatment and care for leukemia may disrupt income and bring about new expenses, including medical bills, co-pays, child care, travel expenses, and more. The Leukemia Research Foundation Patient Grant Program is intended to assist patients and their families by easing the financial burden so they can focus on their health and treatment.

Our Patient Grant Program offers a one-time grant to eligible leukemia or MDS patients living in Illinois or within 100 miles of Chicago.

The maximum grant is $1,500 per applicant.

Required information

Details of your diagnosis, including date, treating hospital, and treating physicians.
Social worker contact information (if applicable).
Information about dependents.
Details of employment status for yourself and your spouse/partner, including dates of hire and income.
A statement describing your request for assistance.

Required documents

Letter from treating physician (or nurse practitioner) confirming leukemia or MDS diagnosis and verifying patient is in active treatment. The letter should be dated no earlier than January 2024.
Copy of applicant household federal tax return for the most recent year (page showing income). If applicant does not file a tax return, a copy of a benefits statement (such as disability) or a copy of a most recent pay stub (for all household members) may be submitted.

Other information

The Leukemia Research Foundation may also request (not required at time of application, but may be requested during application review):

Applicant’s household bank statements from the last three months, including checking, savings, CDs, and money markets.
Verification of employment.
Copy of applicant’s driver’s license or state ID.
Interview with applicant or family member to clarify information in the application.

AI Based Application Success Predictor

1. Strong, Direct Focus on Leukemia

The single most important predictor of success is that the project clearly and explicitly addresses:

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Chronic lymphocytic leukemia (CLL/SLL)

Chronic myeloid leukemia (CML)

Pediatric or AYA leukemia

Myelodysplastic syndromes evolving into leukemia

Leukemia stem cells

Relapse and resistance mechanisms

Immunotherapy or targeted therapy for leukemia

❗ Projects only loosely related to leukemia (general hematology, general cancer, or broad immunology) are typically not competitive.

2. Fit to the LRF "Hollis Brownstein Research Grants Program" Mechanism

LRF’s flagship grant supports:

Early-career independent investigators (e.g., junior faculty, early assistant professors)

Who are starting to build an independent leukemia research lab

With innovative, transformative, and feasible hypotheses

The award is generally one of the first independent research grants for many recipients.

Predictor: Applicants must fit the early-career independent PI profile.

3. Innovation + High-Impact Leukemia Science

LRF prioritizes transformative science that can meaningfully move leukemia research forward.

Highly competitive themes include:

Novel mechanisms of leukemogenesis

New therapeutic targets

Drug resistance pathways

Leukemia cell-of-origin studies

Microenvironment and immune interactions

Novel immunotherapies (CAR-T, bispecific antibodies, NK cell approaches)

Molecular vulnerabilities in relapse disease

Single-cell, multi-omics, or computational leukemia biology

Predictor: Emphasize why your finding could change leukemia diagnosis, treatment, or survival.

4. Strong Preliminary Data

Even though LRF supports early-career investigators, funded applications almost always include:

Pilot experiments

Feasibility data for key assays or models

Signaling pathway or genomic data supporting the hypothesis

Early drug response/phenotype findings

Proof of access to necessary patient samples or datasets

Predictor: Strong feasibility evidence dramatically increases competitiveness.

5. Proper Use of Leukemia-Relevant Models

Successful projects rely on:

Primary human leukemia samples

Appropriate leukemia cell lines

Leukemia PDX models

Genetically engineered mouse models (GEMMs) of AML/ALL

Single-cell transcriptomics from leukemia cohorts

Leukemia organoids/spheroids

Predictor: Using disease-appropriate models is viewed as essential.

6. Clear, Feasible, Focused Specific Aims

LRF grants are 1–2 year awards with modest funding (typically ~$100,000+).

Successful proposals:

Have 2–3 tightly defined, hypothesis-driven aims

Fit the short funding timeline

Include achievable milestones

Avoid overambition

Explicitly support future NIH R01 or R21 proposals

Predictor: Present a realistic, milestone-driven plan.

7. Strong Investigator Potential

Because LRF aims to launch the careers of future leukemia research leaders, they favor applicants who show:

Clear trajectory toward becoming an independent investigator

First-author or senior-author papers in leukemia or related cancer fields

Evidence of technical expertise

Grantsmanship potential

A unique niche distinct from their mentor’s work

Predictor: Demonstrating strong career momentum yields higher scores.

8. High-Quality Mentorship & Environment

For early-career applicants, reviewers focus heavily on:

The strength of the mentor’s track record

Institutional commitment (protected time, resources, lab space)

Access to leukemia clinics, biobanks, or mouse cores

A strong scientific environment for leukemia research

Predictor: A well-supported environment signals high likelihood of success.

9. Clear Writing, Strong Logic, and Good Figures

Highly rated applications demonstrate:

Clean, compelling storytelling

Data presented in a visually clear manner

Strong justification of how the hypothesis arose

A well-organized approach and analysis plan

Predictor: Excellent writing significantly boosts reviewer enthusiasm.

10. Pathway to Future Leukemia Funding

LRF reviewers want to see:

A clear path toward future NIH, DoD, or foundation grants

How the project will generate preliminary data for R01/R21/K applications

Strategic vision for a multi-year leukemia research program

Predictor: Show that LRF support = catalytic step toward independence.

🏆 Summary Table — Key Predictors

Predictor	Why It Matters
Strong leukemia-specific focus	Core mission requirement
Early-career independent PI	Required for main LRF mechanisms
Innovation + impact	Primary scoring area
Preliminary data	Demonstrates feasibility
Proper disease models	Ensures translational relevance
Focused Specific Aims	Fits short timeline & budget
Investigator potential	Aligns with LRF mission
Mentorship & environment	Supports successful execution
Clear writing & logic	Influences reviewers strongly
Pathway to future funding	Critical for early-career awards

Specialties

Clinical Trials

Neurosciences

Eligibility Requirements

Applicant must reside within the state of Illinois or within 100 miles of Chicago.
Applicant must have a leukemia or MDS diagnosis.
Applicant household income can be no more than 400% of the federal government’s poverty level. See below.
This is a one-time grant. Grant recipients are not eligible to apply again in subsequent years.

Sponsor Details

Sponsor Institute/Organizations: Leukemia Research Foundation

Sponsor Type: Corporate/Non-Profit

Address: 191 Waukegan Road, Suite 105 Northfield, Illinois 60093 847.424.0600 info@leukemiarf.org EIN# 36-6102182

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity